Krystal Biotech, Inc. Common Stock vs. X4 Pharmaceuticals, Inc. Common Stock
KRYS
Krystal Biotech, Inc. Common Stock
$343.81 -2.12%
VS XFORX4 Pharmaceuticals, Inc. Common Stock
$3.50 -13.24%
X4 Pharmaceuticals, Inc. Common Stock (XFOR) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| KRYS | XFOR | |
|---|---|---|
| Market Cap | $10.40 billion | $347.51 million |
| Revenue (TTM) | $440.48 million | — |
| Net Income (TTM) | $241.47 million | — |
KRYS leads on 1 of 1 size & scale factors.
Valuation
| KRYS | XFOR | |
|---|---|---|
| P/E Ratio | 43.08 | — |
| Price / Book | 7.65 | 2.24 |
| Price / Sales | 23.60 | — |
XFOR leads on 1 of 1 valuation factors.
Profitability
| KRYS | XFOR | |
|---|---|---|
| Net Margin | 54.82% | — |
| Return on Equity | 17.77% | — |
KRYS and XFOR split the profitability factors evenly.
Risk & Sentiment
| KRYS | XFOR | |
|---|---|---|
| Short Interest | 0.11% | 0.08% |
XFOR leads on 1 of 1 risk & sentiment factors.
Dig deeper: KRYS overview, KRYS financials, XFOR overview, XFOR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.